Cargando…
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
BACKGROUND: TP53 defects, i.e. 17p13 deletion and/or nucleotide mutations, associate with short survival and chemorefractoriness in chronic lymphocytic leukemia (CLL). In this context, since direct sequencing of the TP53 gene does not evaluate TP53 functionality, a functional assessment of TP53 path...
Autores principales: | Pozzo, Federico, Dal Bo, Michele, Peragine, Nadia, Bomben, Riccardo, Zucchetto, Antonella, Rossi, Francesca Maria, Degan, Massimo, Rossi, Davide, Chiarenza, Annalisa, Grossi, Alberto, Di Raimondo, Francesco, Zaja, Francesco, Pozzato, Gabriele, Secchiero, Paola, Gaidano, Gianluca, Del Poeta, Giovanni, Zauli, Giorgio, Foà, Robin, Guarini, Anna, Gattei, Valter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222122/ https://www.ncbi.nlm.nih.gov/pubmed/24283248 http://dx.doi.org/10.1186/1756-8722-6-83 |
Ejemplares similares
-
TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023) -
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells
por: Dal Bo, Michele, et al.
Publicado: (2015) -
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023) -
Nutlin‐3a selects for cells harbouring TP
53 mutations
por: Kucab, Jill E., et al.
Publicado: (2016) -
Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)